[en] Changes in ionotropic glutamate (Glu) N-methyl-D-aspartic acid (NMDA), and 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) receptors in rat forebrain regions were autoradiographically quantified after continuous infusion of JL 13 [(5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine furnarate] for 28 days using osmotic minipumps, and compared to the effects of representative typical (haloperidol) and atypical (clozapine, olanzapine, and risperidone) antipsychotic drugs from previous studies. Similar to other atypical and not typical antipsychotics, JL 13 decreased labeling of NMDA receptors in medial and lateral caudate-putamen (CPu; by 40%). These findings indicate that downregulation of NMDA receptors by JL 13 and other atypical antipsychotic agents in CPu may contribute to their low risk of extrapyramidal side effects. In addition, and similar to olanzapine and risperidone, JL 13 increased AMPA receptor binding in CPu (by 42%). Changes in AMPA receptors may contribute to psychopharmacological properties of JL 13 and other atypical agents. Similar to clozapine, JL 13 did not alter levels of NMDA and AMPA receptors in hippocampus and entorhinal cortex. Long-term effects of JL 13 on ionotropic Glu receptors, as well as on other dopamine and serotonin receptors, support the atypical antipsychotic profile of this novel agent.
Aghajanian, G. K., & Marek, G. J. (2000). Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Research Reviews, 31, 302-312.
Baldessarini, R. J., & Tarazi, F. I. (2005). Pharmacotherapy of psychosis and mania. In L. L. Brunton, J. S. Lazo, & K. L. Parker (Eds.), Goodman and Gilman's the pharmacological basis of therapeutics (pp. 461-500). New York: McGraw-Hill.
Boegman, R. J., & Vincent, S. R. (1996). Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse, 22, 70-77.
Bruhwyler, J., Liégeois, J.-F., Bergman, J., Carey, G., Goudie, A., Taylor, A., et al. (1997). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioral properties. Pharmacoligical Research, 36, 255-264.
Cai, X., Gu, Z., Zhong, P., Ren, Y., & Yan, Z. (2002). Serotonin 5-HT1A receptors regulate AMPA receptor channels through inhibiting Ca2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. Journal of Biological Chemistry, 277, 36553-36562.
Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annual Review of Pharmacology and Toxicology, 41, 237-260.
Casey, D. E., Bruhwyler, J., Delarge, J., Géczy, J., & Liégeois, J.-F. (2001). The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. Psychopharmacology, 157, 228-235.
Conn, P. J., & Pin, J. P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology, 37, 205-237.
Ellenbroek, B. A., & Liégeois, J.-F. (2003). JL 13, an atypical antipsychotic: A preclinical review. CNS Drug Reviews, 9, 41-56.
Ellenbroek, B. A., Liégeois, J.-F., Bruhwyler, J., & Cools, A. R. (2001). Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 298, 386-391.
Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in sub-regions of human hippocampus: Effects of schizophrenia. American Journal of Psychiatry, 157, 1141-1149.
Goff, D. C., & Coyle, J. T. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry, 158, 1367-1377.
Goff, D. C., Leahy, L., Berman, I., Posever, T., Herz, L., Leon, A. C., et al. (2001). A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of Clinical Psychopharmacology, 21, 484-487.
Hollmann, M., & Heinemann, S. (1994). Cloned glutamate receptors. Annual Review of Neuroscienceci, 17, 31-108.
Invernizzi, R., Garavaglia, C., & Samanin, R. (2000). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 361, 298-302.
Javitt, D. C., & Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301-1308.
Krieckhaus, E. E., Donahoe, J. W., & Morgan, M. A. (1992). Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biological Psychiatry, 31, 560-570.
McCoy, L., Cox, C., & Richfield, E. K. (1996). Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. European Journal of Pharmacology, 318, 41-45.
McCoy, L., Cox, C., & Richfield, E. K. (1998). Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse, 28, 195-207.
Meador-Woodruff, J. H., & Healy, D. J. (2000). Glutamate receptor expression in schizophrenic brain. Brain Research Reviews, 31, 288-294.
Moran-Gates, T., Massari, C., Graulich, A., Liégeois, J. F., & Tarazi, F. I. (2006). Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. Journal of Neuroscience Research, 84, 675-682.
Ozawa, S., Kamiya, H., & Tsuzuki, K. (1998). Glutamate receptors in the mammalian central nervous system. Progress in Neurobiology, 54, 581-618.
Paxinos, F., & Watson, C. (1982). The rat brain in stereotaxic coordinates. New York: Academic Press.
Riva, M. A., Tascedda, F., Lovati E., & Racagni, G. (1997). Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Molecular Brain Research, 50, 136-142.
Schmidt, W. J., & Bubser, M. (1989). Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacology, Biochemistry and Behavior, 32, 621-623.
Spurney, C. F., Baca, S. M., Murray, A. M., Jaskiw, G. E., Kleinmann, J. E., & Hyde, T. M. (1999). Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse, 34, 266-276.
Tarazi, F. I., Baldessarini, R. J., Kula, N. S., & Zhang, K. (2003). Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: Implications for antipsychotic drug treatment. Journal of Pharmacology and Experimental Therapeutics, 306, 1145-1151.
Tarazi, F. I., Florijn, W. J., & Creese, I. (1996). Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology, 128, 371-379.
Tarazi, F. I., Zhang, K., & Baldessarini, R. J. (2000). Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain Research, 881, 69-72.
Tascedda, F., Blom, J. M., Brunello, N., Zolin, K., Gennarelli, M., Colzi, A., et al. (2001). Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biological Psychiatry, 50, 117-122.
Tascedda, F., Lovati, E., Blom, J. M., Muzzioli, P., Brunello, N., Racagni, G., et al. (1999). Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology, 21, 211-217.
Tsai, G., & Coyle, J. T. (2002). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology, 42, 165-179.
Wullner, U., Testa, C. M., Catania, M. V., Young, A. B., & Penney, J. B. (1994). Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions. Brain Research, 645, 98-102.
Yoshida, Y., Ono, T., Kizu, A., Fukushima, R., & Miyagishi, T. (1991). Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. European Journal of Pharmacology, 203, 173-180.
